An observational study in Brain Tumor, sponsored by Universitas Sumatera Utara. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Universitas Sumatera Utara · Observational
This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance
This study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. Samples were collected from patients at Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for these variables. Sample collection began in March - September 2020. The sample obtained was 35 people who met the inclusion and exclusion criteria.
Inclusion criteria:
Exclusion criteria:
Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically.
Based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.
1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.
This study's enrollment of 35 is below the median of 100 across 380 observational studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →Universitas Sumatera Utara is the lead sponsor of 23 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Samples were collected from patients at Haji Adam Malik Hospital in Medan, Sample collection began in March - September 2020
Exclusion Criteria:
This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor. After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
Diagnostic Test: Procalcitonin
This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor. After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
Diagnostic Test: Procalcitonin
This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
Diagnostic Test: Procalcitonin
Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
Also known as: C-Reactive Protein (CRP), Neutrophyl to Lymphocyte Ratio (NLR)
Value of Procalcitonin
Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Time frame: February-April 2020
Value of C-Reactive Protein
Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Time frame: April- June 2020
Value of Neutrophyl to Lymphocyte Ratio (NLR)
Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Time frame: June- August 2020
Demographic of samples
Demographic of each samples such as age, gender, Glassgow coma scale and Karnofsky score
Time frame: August- October 2020
Plan to share: Undecided
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitas Sumatera Utara